TG Therapeutics: The Business Is More Attractive Than The Valuation (NASDAQ:TGTX)

seekingalpha.com · 2026-10-27

TG Therapeutics delivered strong BRIUMVI sales growth, raising 2024 revenue guidance and approaching blockbuster status. Learn why TGTX stock is a hold.

TickrTrends take: TG Therapeutics operates in the Healthcare sector and is currently assessed as undervalued by TickrTrends metrics. For investors focused on valuation, the gap between the company's business fundamentals and its current market price represents the key dynamic to monitor as the healthcare landscape continues to evolve. Tracking how the market reprices TGTX relative to its operational performance will indicate whether this valuation disconnect persists or narrows over time.

Read the full story at seekingalpha.com →